Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Pfizer Plans $75 Million Fund to Address Shareholder Suits
NY Times
Saturday, December 4, 2010 - 12:19pm
tags:
Pfizer, investors, lawsuits
Setback for Valeant Epilepsy Drug
Yahoo/Zacks
Saturday, December 4, 2010 - 12:18pm
tags:
Valeant Pharmaceuticals, epilepsy, ezogabine, GSK
Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
Yahoo/PR NewsWire
Saturday, December 4, 2010 - 12:17pm
tags:
Pfizer, Bosutinib, chronic myeloid leukemia
Impax Laboratories Confirms Patent Challenge Relating to INTUNIVTM, 4 mg
Yahoo/BusinessWire
Saturday, December 4, 2010 - 12:16pm
tags:
Impax Labs, Shire Development Inc, Intuniv, ADHD
Neutral on Incyte
Yahoo/Zacks
Saturday, December 4, 2010 - 12:15pm
tags:
Incyte, investors
Pfizer Properly Warned Woman's Doctors on Prempro Health Risks, Jury Finds
Bloomberg
Saturday, December 4, 2010 - 12:14pm
tags:
Pfizer, lawsuits, Prempro
Which Drugmakers Will Take You Higher?
Minyanville
Saturday, December 4, 2010 - 12:13pm
tags:
Novartis, GSK, JNJ, Pfizer, AstraZeneca
BioCryst Reports New Data from Its Phase 2 Forodesine Study in Patients with Chronic Lymphocytic Leukemia at the 52nd Annual American Society of Hematology Meeting
Yahoo/BusinessWire
Saturday, December 4, 2010 - 12:04pm
tags:
Biocryst, Forodesine, leukemia, chronic lymphocytic leukemia
Cell Therapeutics appeals FDA decision on Pixuvir
Yahoo/AP
Saturday, December 4, 2010 - 12:02pm
tags:
Cell Therapeutics, Pixuvri, non-Hodgkin's lymphoma
Nile Therapeutics Receives NASDAQ Notice; Will Request Hearing
Yahoo/PR NewsWire
Saturday, December 4, 2010 - 12:00pm
tags:
Nile Therapeutics, investors
Human Genome Sciences and GlaxoSmithKline Announce FDA Extension of BENLYSTA® PDUFA Target Date to March 10, 2011
Yahoo/BusinessWire
Saturday, December 4, 2010 - 11:58am
tags:
Human Genome Sciences, GSK, Benlysta, PDUFA
GlaxoSmithKline Grows Theravance Stake: Investing in the Pipeline
Seeking Alpha
Saturday, December 4, 2010 - 11:57am
tags:
GSK, Theravance
Medicis Suit Claims Aurobindo Infringes U.S. Patents for Solodyn Acne Drug
Bloomberg
Saturday, December 4, 2010 - 11:55am
tags:
Medicis, Aurobindo, Solodyn, acne, lawsuits
Pfizer Properly Warned About Prempro Health Risks, Jury Finds
Bloomberg
Friday, December 3, 2010 - 11:31am
tags:
Wyeth, Pfizer, Prempro, HRT
FDA: Proposed Weight Loss Drug Contrave Raises Blood Pressure
WSJ Online
Friday, December 3, 2010 - 11:06am
tags:
FDA, obesity, Contrave, hypertension, Orexigen
Cyclacel rallies on drug update
Marketwatch
Friday, December 3, 2010 - 11:04am
tags:
Cyclacel, Sapacitabine, MDS
Insurers Force How Much Generic Switching?
Pharmalot
Friday, December 3, 2010 - 11:01am
tags:
insurance, generics, generic switching
Gilead Sciences: Nice Cash Flow, But What’s in the Pipe?
Seeking Alpha
Friday, December 3, 2010 - 10:59am
tags:
Gilead Sciences, pipelines
200 Day Level, Key For Sanofi-Aventis
Traders Huddle
Friday, December 3, 2010 - 9:31am
tags:
Sanofi
Orexigen's Diet Pill Has Unclear Benefits, an FDA Staff Review Indicates
Bloomberg
Friday, December 3, 2010 - 8:46am
tags:
Orexigen, FDA, Contrave, obesity

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.